# Hypertension Management: Evidence-Based Clinical Guide

## Learning Objectives

After reviewing this handout, students should be able to: 1. Classify hypertension stages and understand measurement standards 2. Describe the role of out-of-office blood pressure monitoring in diagnosis 3. Identify first-line antihypertensive medications and their mechanisms 4. Apply evidence-based blood pressure targets based on patient risk 5. Recognize and manage special populations (diabetes, CKD, pregnancy, resistant HTN) 6. Interpret 2025 ACC/AHA guideline recommendations for treatment decisions

------------------------------------------------------------------------

## Section 1: Blood Pressure Classification and Measurement

### Hypertension Definitions (2025 Guidelines)

| Office category      | Average office BP (mmHg)            |
|----------------------|-------------------------------------|
| Normal               | \<120 and \<80                      |
| Elevated             | 120–129 and \<80                    |
| Stage 1 hypertension | 130–139 systolic OR 80–89 diastolic |
| Stage 2 hypertension | ≥140 systolic OR ≥90 diastolic      |

These categories use office measurements. Home and ambulatory measurements require the corresponding thresholds below.

### Standardized Measurement Technique

**Critical elements for accurate office BP measurement:** - Patient seated 5 minutes with back supported, feet flat, arm at heart level - Proper cuff size (bladder encircles 80-100% of arm circumference) - Avoid caffeine, exercise, smoking for 30 minutes pre-measurement - Empty bladder before measurement - Take 2-3 readings 1-2 minutes apart; average the readings

**Oscillometric vs. Auscultatory Methods:** - Automated oscillometric devices preferred over manual auscultatory methods (Class 2a) - Oscillometric advantages: reproducibility, eliminates terminal digit bias, standardization - Disadvantage: algorithms are proprietary; only MAP directly measured, SBP/DBP are derived

### Out-of-Office Monitoring (Essential for Diagnosis)

**Home Blood Pressure Monitoring (HBPM):** - Recommended: 7 consecutive days, 2 readings morning/evening, discard day 1 - Threshold for hypertension: ≥130/80 mmHg (home average) - Preferred timing: morning pre-medication (captures trough effect) - Advantages: multiple readings, eliminates white coat effect, superior prognostic value

**Ambulatory Blood Pressure Monitoring (ABPM) - Gold Standard:** - Interpret ABPM using the measurement period and the selected office threshold. In the 2025 AHA/ACC correspondence table, office 130/80 mmHg corresponds to home/daytime 130/80, 24-hour 125/75, and nighttime 110/65. Office 140/90 corresponds to home/daytime 135/85, 24-hour 130/80, and nighttime 120/70. Do not mix thresholds from these two office frameworks. ABPM also identifies nocturnal patterns and white-coat or masked hypertension.

### White Coat vs. Masked Hypertension

| Phenotype | Office BP | Home BP (ABPM uses period-specific thresholds) | Prevalence | Cardiovascular Risk |
|----|----|----|----|----|
| **Normotension** | \<130/80 | \<130/80 | 60-70% | Baseline |
| **White Coat HTN** | 130-159/80-99 | \<130/80 | 15-30% | 1.2× baseline (low) |
| **Masked HTN** | \<130/80 | ≥130/80 | 10-15% | 1.6× baseline (significant) |
| **Sustained HTN** | ≥130/80 | ≥130/80 | ~20% | 2-3× baseline |

**Clinical Pearl:** Always exclude white coat hypertension before treating Stage 1 HTN. Masked hypertension carries significant risk—screen patients with normal office BP but target organ damage.

------------------------------------------------------------------------

## Section 2: Blood Pressure Targets and Risk Stratification

### PREVENT Cardiovascular Risk Calculator

The 2025 guidelines introduce PREVENT (Predicting Risk of CVD Events and Nonfatal Talk) equations—more accurate than older Pooled Cohort Equations by incorporating contemporary preventive therapies.

**Treatment Thresholds:** - **Stage 1 HTN (130-139/80-89) + PREVENT risk \<7.5%**: Lifestyle modification for 3-6 months; consider meds if lifestyle fails - **Stage 1 HTN + PREVENT risk ≥7.5%**: Initiate pharmacotherapy - **Stage 2 HTN (≥140/90)**: Initiate pharmacotherapy regardless of risk (Class 1)

### Blood Pressure Targets by Population

| Population | Target SBP | Special Considerations |
|----|----|----|
| **General/Diabetes/CKD** | \<130/80 mmHg | 2025 AHA/ACC, ADA; in CKD, KDIGO 2021 suggests systolic \<120 on standardized measurement |
| **Coronary artery disease** | \<130 mmHg | Avoid J-curve (DBP \<60 increases coronary risk) |
| **Heart failure** | \<130 mmHg | RAAS inhibitors mandatory |
| **Acute stroke** | 140 mmHg (ICH) | Avoid aggressive reduction post-ischemic stroke |
| **Resistant HTN** | \<130 mmHg | Often requires 4+ agents |
| **Elderly (\>75 yrs)** | \<130 mmHg | Monitor for orthostasis; avoid \<110 SBP |

**SPRINT:** Intensive SBP targeting reduced the primary cardiovascular composite in the selected trial population (HR 0.75), with median follow-up 3.26 years. Absolute benefit depends on baseline risk and follow-up. Assess adverse effects and use standardized measurement. [Primary report](https://pubmed.ncbi.nlm.nih.gov/26551272/).

------------------------------------------------------------------------

## Section 3: First-Line Antihypertensive Medications

### The Four Foundation Drug Classes

**1. ACE Inhibitors (ACEI) – Mechanism: Blocks angiotensin I→II conversion**

| Agent | Mechanism | Unique Features | Cautions |
|----|----|----|----|
| Lisinopril | Renal elimination (100%) | Long half-life (40-50 hrs in CKD) | Cough 10.6%, angioedema 0.3% |
| Ramipril | Hepatic + renal | HOPE trial cardioprotection | Cough, hyperkalemia risk |
| Fosinopril | Hepatic (80%) | Preferred in CKD (short washout to ARNI) | Well tolerated |
| Perindopril | Active metabolite | Ultra-long acting | Extended washout if ARNI transition |

**Side Effects (Absolute Risk):** - Persistent cough: 10.6% (NNH 13 vs. ARBs) - Angioedema: 0.3% (serious, may recur years into therapy) - Hyperkalemia: 5.3% in general population; 9.7% in CKD stage 4-5

**2. Angiotensin Receptor Blockers (ARB) – Mechanism: AT₁ receptor antagonism**

| Agent | Unique Properties | Indication |
|----|----|----|
| **Losartan** | Uricosuric (0.6-1.1 mg/dL UA reduction); CYP2C9 pro-drug | Hyperuricemia/gout + HTN |
| **Telmisartan** | Longest half-life (24 hrs); ONTARGET trial | Once-daily dosing convenience |
| **Valsartan** | Used in ARNIs; well-studied CKD | Albuminuria reduction |

**Advantages over ACEIs:** - No cough (0.4% vs. 10.6%) - Lower angioedema risk (0.11% vs. 0.3%) - Similar BP reduction and CV outcomes - Better adherence (33% fewer discontinuations)

**3. Calcium Channel Blockers (CCB) – Mechanism: L-type calcium antagonism → arteriolar vasodilation**

| Subclass | Agent | Half-Life | Comments |
|----|----|----|----|
| **Dihydropyridines** | Amlodipine | 30-50 hrs | No reflex tachycardia; edema common |
|  | Extended-rel nifedipine | 24 hrs | Avoid immediate-release (excessive variability) |
| **Non-dihydropyridines** | Diltiazem | 3-4 hrs | Negative inotrope; bradycardia risk |
|  | Verapamil | 3-7 hrs | Constipation; contraindicated in HFrEF |

**Clinical Pearl:** Dihydropyridine CCBs (e.g., amlodipine) maintain cardiac output and don’t cause reflex tachycardia—preferred in most patients.

**4. Thiazide and Thiazide-Like Diuretics – Mechanism: Renal tubular sodium/chloride reabsorption block**

| Agent | Potency Ratio | Half-Life | Use |
|----|----|----|----|
| Hydrochlorothiazide (HCTZ) | 1.0 | 5-14 hrs | Avoid if possible (less potent, shorter acting) |
| **Chlorthalidone** | 1.5-2.0× HCTZ | 40-60 hrs | **Preferred** (superior BP reduction, sustained effect) |
| **Indapamide** | 1.5-2.0× HCTZ | 14-18 hrs | Good alternative to chlorthalidone |

**Key Metabolic Effects:** - Hypokalemia: 5-10%, especially at doses \>25 mg daily - Hyperglycemia: 2-3% new-onset diabetes - Hyperuricemia: may precipitate gout - Dyslipidemia: modest increases in total cholesterol

**Renal Pearl:** Despite metabolic effects, thiazides are still Class 1 for hypertension. Monitor electrolytes 4-12 weeks after initiation.

------------------------------------------------------------------------

## Section 4: Special Populations and Comorbidities

### Diabetes Mellitus

**BP Target:** \<130/80 mmHg (Class 1) — the 2025 AHA/ACC guideline and the ADA Standards of Care. If CKD coexists, KDIGO 2021 suggests systolic \<120 mmHg when tolerated, on standardized office measurement.

**Preferred Medications:** 1. RAAS inhibitors (ACEI/ARB) – **mandatory with any albuminuria** (including \<30 mg/g) 2. Add CCB if not at goal with RAAS inhibitor monotherapy 3. Thiazide diuretic as second/third agent 4. Avoid dual RAAS blockade (ACEI + ARB or DRI) – increased HK, AKI, hypotension without CV benefit (Class 3 Harm)

**Synergistic Agents:** - GLP-1 agonists: 3-5 mmHg reduction + CV protection - SGLT2 inhibitors: 2-3 mmHg reduction + renal/HF protection

------------------------------------------------------------------------

### Chronic Kidney Disease (CKD)

**BP Target:** \<130/80 mmHg across **all CKD stages** (Class 1) — the 2025 AHA/ACC guideline and the ADA Standards of Care.

KDIGO 2021 (Blood Pressure in CKD) suggests a target systolic \<120 mmHg when tolerated, using standardized office measurement (grade 2B, driven by the CKD subgroup of SPRINT). It explicitly excludes kidney transplant recipients and patients on dialysis. Much of the gap is measurement technique rather than disagreement about physiology: KDIGO’s lower number presumes a standardized or unattended reading, which most routine clinic cuffs do not meet.

**Obligatory Therapy:** - RAAS inhibition for albuminuric patients (≥30 mg/g creatinine) – renoprotective (Class 1) - Acceptable 30% creatinine rise in first 2-4 weeks (hemodynamic response, not progressive) - Add SGLT2 inhibitor for additive renal protection

**Monitoring Parameters:** - Check K+, Cr 1-2 weeks after RAAS inhibitor initiation - If K+ \>5.5 mEq/L or Cr rise \>30%: confirm true progression (repeat, rule out dehydration) - Urine-ACR at baseline and annually to assess albuminuria response

**Clinical Pearl:** ABPM (24-hour) more strongly predicts renal outcomes than office BP in CKD.

------------------------------------------------------------------------

### Resistant Hypertension

**Definition:** SBP ≥140 mmHg despite 3+ optimally-dosed medications (including diuretic), or requiring ≥4 agents to achieve goal.

**Evaluation Algorithm:** 1. **Confirm true resistance:** ABPM to rule out white coat effect (37.5% of apparent resistance) 2. **Assess adherence:** Pharmacy refill history, drug levels (lowest cost screening) 3. **Exclude secondary causes:** Primary aldosteronism (Class 1 universal screening regardless of K+ level—normokalemic phenotype common), RAS, OSA, hyperparathyroidism, hyperthyroidism 4. **Address modifiable factors:** Dietary sodium, NSAID/stimulant use, sleep apnea treatment

**Fourth-Line Agent:** - **Spironolactone (MRA):** 20-25 mmHg additional reduction in resistant HTN (Class 1) - Requires eGFR ≥45 mL/min (check K+ closely) - Typical dose: 12.5-25 mg daily

------------------------------------------------------------------------

### Primary Aldosteronism

**New Guideline: Universal screening in resistant HTN regardless of potassium status (Class 1)**

**Rationale:** 70-80% of primary aldosteronism is normokalemic; old practice missed most cases.

**Screening Test:** Morning seated aldosterone-to-renin ratio (ARR)

**Treatment:** Mineralocorticoid receptor antagonist (spironolactone/eplerenone) reduces CV risk beyond BP control alone.

------------------------------------------------------------------------

### Hypertension in Pregnancy

**Classification:** - Normal: \<120/80 mmHg - Elevated: 120-129/\<80 - Stage 1 HTN: 130-139/80-89 - Stage 2 HTN: ≥140/90 - **Hypertensive crisis (urgent treatment): ≥160/110**

**Treatment Thresholds (CHAP Trial):** - Treat chronic HTN ≥140/90 mmHg in pregnancy (Class 1) - Advantages: 25% reduction in preeclampsia, no increased fetal risk

**Preferred Medications:** 1. **Methyldopa** – gold standard (safest long-term) 2. **Labetalol** – excellent (avoid in asthma) 3. **Extended-release nifedipine** – safe alternative

**Contraindicated (Teratogenic/Harmful):** - ACE inhibitors, ARBs (2nd/3rd trimester teratogenesis) - Atenolol (intrauterine growth restriction) - Enalapril, lisinopril, etc. - Spironolactone (anti-androgenic)

**Hypertensive Emergency in Pregnancy:** Acute severe BP in pregnancy or postpartum is systolic ≥160 OR diastolic ≥110 mmHg. Confirm persistence promptly (typically over 15 minutes) and initiate treatment as soon as possible within 30–60 minutes of confirmed severe hypertension. First-line options include IV labetalol, IV hydralazine, or immediate-release nifedipine taken orally, particularly when IV access is unavailable. Do not administer nifedipine sublingually. Use the obstetric emergency protocol with frequent maternal and fetal assessment; avoid excessive BP reduction. [ACOG Committee Opinion 767](https://pubmed.ncbi.nlm.nih.gov/30575639/).

------------------------------------------------------------------------

## Section 5: 2025 Guideline Innovations

### Potassium-Based Salt Substitutes (NEW)

**Class 2a recommendation** for agents containing 25% KCl / 75% NaCl

**Evidence (SSaSS Trial):** - 3.34 mmHg systolic reduction - 13% stroke risk reduction - Dual benefit: ↓ Na+, ↑ K+

**Contraindications:** - eGFR \<30 mL/min (hyperkalemia risk) - Concurrent potassium-sparing diuretics or RAAS inhibitors (additive HK risk) - Baseline hyperkalemia

------------------------------------------------------------------------

### Renal Denervation (Class 2b)

**Candidates:** - Office SBP 140-180 mmHg despite adherence - eGFR ≥40 mL/min - No significant renal artery abnormalities - Multidisciplinary team evaluation required

**Efficacy:** 5-10 mmHg office SBP reduction (modest); 30-40% non-responders; durability uncertain.

**Clinical Pearl:** Not a replacement for pharmacotherapy; combined with optimal medications for best outcomes.

------------------------------------------------------------------------

## Section 6: Clinical Pearls & Practice Points

### Measurement & Diagnosis

- **Exclude white coat HTN** before treating Stage 1: use ABPM/HBPM for office BP 130-159/80-99
- **Screen for masked HTN** in patients with normal office BP + target organ damage
- **Morning surge** (\>35 mmHg) independently predicts stroke risk beyond mean BP

### Drug Selection

- **ACEI cough?** Switch to ARB (avoids recurrence)
- **Losartan for gout:** unique uricosuric effect
- **Chlorthalidone over HCTZ:** superior potency and duration
- **Avoid dual RAAS blockade:** increased AKI, HK, hypotension (Class 3 Harm)

### Special Scenarios

- **Diabetes + albuminuria:** RAAS inhibitor mandatory (even microalbuminuria)
- **CKD stages 4-5:** Anticipate prolonged ACE-I half-life if future ARNI transition needed
- **Resistant HTN:** Screen for primary aldosteronism universally (regardless of K+)
- **Wide pulse pressure (PP \>60 mmHg):** Avoid DBP \<60 mmHg (increases coronary events in CAD)

### Target Organ Monitoring

- Check eGFR, K+ 1-2 weeks after RAAS inhibitor
- Annual urine ACR in diabetes/CKD
- Consider ABPM annually in high-risk patients even if controlled
- Renal ultrasound if eGFR decline \>30% in 3 months

------------------------------------------------------------------------

## Practice Questions

**Question 1:** A 52-year-old woman has office BP 138/87 mmHg with no symptoms. She is not on medications. Home BP monitoring over 7 days (after discarding day 1) averages 127/78 mmHg. What is the most appropriate next step?

1.  Initiate monotherapy with amlodipine
2.  Diagnose white coat hypertension; counsel on lifestyle modification and reassess in 3-6 months
3.  Obtain ABPM to confirm
4.  Begin chlorthalidone for BP control

**Answer: B** – Office BP 138/87 with home BP \<130/80 defines white coat HTN. Lifestyle modification with reassessment in 3-6 months is Class 2a recommended; ABPM is optional confirmatory testing.

------------------------------------------------------------------------

**Question 2:** A 68-year-old man with type 2 diabetes (HbA1c 7.2%) and CKD stage 3b (eGFR 38) has BP 142/88 despite lisinopril 10 mg daily. Serum K+ 5.2 mEq/L. Which medication would you add next?

1.  Spironolactone 12.5 mg for resistant HTN
2.  Hydrochlorothiazide 12.5 mg
3.  Amlodipine 5 mg
4.  Increase lisinopril to 20 mg

**Answer: C** – Amlodipine is appropriate second-line; avoids further K+ elevation (given borderline hyperkalemia and RAAS inhibitor). Spironolactone inappropriate here (baseline HK). HCTZ less preferred than chlorthalidone/indapamide. Increasing ACEI would worsen HK.

------------------------------------------------------------------------

**Question 3:** A 44-year-old woman in her second trimester with chronic hypertension (BP 148/92 mmHg) is currently on lisinopril. What is the most appropriate management?

1.  Continue lisinopril; it is safe throughout pregnancy
2.  Switch to methyldopa or labetalol immediately
3.  Obtain obstetric consultation and initiate treatment if risk of preeclampsia \>10%
4.  Defer treatment until third trimester

**Answer: B** – ACE inhibitors are teratogenic in 2nd/3rd trimester (enalapril-associated renal dysgenesis). Switch to methyldopa or labetalol. Treatment threshold is ≥140/90 per CHAP trial (Class 1), so treatment is indicated.

------------------------------------------------------------------------

## See Also

### Related Student Handouts

- Secondary Hypertension
- Blood Pressure Measurement
- IV Antihypertensives for Hypertensive Urgency/Emergency
- CKD Complications
- Cardiorenal Syndrome

### Clinical Content (01-Clinical-Medicine/Nephrology & Cardiology)

- Hypertension Management Hub
- Cardio-Renal Ecosystem Hub
- Essential Renal Laboratory Tests

### Butler-COM Resources

- Butler COM - Nephrology Deep Dive

------------------------------------------------------------------------

## Key References

- Writing Committee Members\*, Jones DW, Ferdinand KC, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40811497/)
- Hypertension Management Evidence Based Report
- Oscillometric Blood Pressure Measurement Clinical Applications
- Home Blood Pressure Monitoring Patient Guide

------------------------------------------------------------------------

**Created for PA/Medical Student Education** *Last Updated: 2026-02-12*

## Clinical Resources

- Clinical Review: Hypertension Management Patient Bp Monitoring Guide — Comprehensive clinical review with PubMed references
- Clinical Review: Renovascular Hypertension Review — Comprehensive clinical review with PubMed references
- Clinical Review: Hypertension Management Report — Comprehensive clinical review with PubMed references

### Also on this topic

The same subject at other levels of depth.

- **Lecture:** [🌅 Morning Hypertension Management](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/morning-hypertension.html)
- **Interactive case:** [Outpatient Hypertension Management](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case9_enhanced.html)
- **Clinical Mastery deep dive:** [Comprehensive Hypertension Management](https://urinenephrology.org/mastery/hypertension-advanced/comprehensive-management.html)


---

[Website version](https://urinenephrology.org/student-resources/hypertension/hypertension-management-student-handout.html) · Markdown synchronized October 3, 2026.